Warner Financial Inc. Has $338,000 Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Warner Financial Inc. has reduced its holdings in Johnson & Johnson (JNJ) by 60.4%, owning 2,211 shares worth approximately $338,000 as of their latest filing.
• JPMorgan Chase & Co. and other analysts have increased their target prices for Johnson & Johnson, with JPMorgan raising it from $185.00 to $200.00 and maintaining a "neutral" rating.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, representing an annualized yield of 2.8%, with a current dividend payout ratio of 55.61%.

Warner Financial Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 60.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,211 shares of the company's stock after selling 3,372 shares during the period. Warner Financial Inc.'s holdings in Johnson & Johnson were worth $338,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in JNJ. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $218,000. Signal Advisors Wealth LLC boosted its position in Johnson & Johnson by 7.1% in the first quarter. Signal Advisors Wealth LLC now owns 8,531 shares of the company's stock valued at $1,415,000 after buying an additional 562 shares in the last quarter. Procyon Advisors LLC boosted its position in Johnson & Johnson by 14.6% in the first quarter. Procyon Advisors LLC now owns 62,994 shares of the company's stock valued at $10,300,000 after buying an additional 8,048 shares in the last quarter. Finally, Prospect Financial Services LLC acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $268,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Tuesday, September 16th. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a research report on Friday, September 19th. Finally, Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the company an "overweight" rating in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $188.88.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $188.51 on Friday. The firm has a market cap of $453.98 billion, a PE ratio of 20.16, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The firm's fifty day moving average is $176.18 and its 200-day moving average is $162.83. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $189.78.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the business earned $2.82 earnings per share. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.